Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDIGO: Individualized Treatment for Metastatic Non-clear Cell Renal Cell Carcinoma
NCT04644432Phase 2Unknown
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Mar 2020
- Primary completion
- Sep 2022
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of erlotinib, osimertinib, alectinib, dabrafenib + trametinib, trametinib and 9 more, sponsored by Herlev & Gentofte Hospital. Status: unknown.
02
Drugs
Beyond the preview
Go deeper on NCT04644432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04644432.